IP Library › Granted Patent US 11,129,843
Granted Patent B2
US 11,129,843 · App. 16/607,531 · Granted Sep 28, 2021

Treating and preventing kidney damage

Inventors: Eric A. Marcotulli (New York, NY); Daniel A. Alminana (New York, NY); Leonard Pershing Guarente (Newton, MA); Ryan Dellinger (Azusa, CA); Mark Morris (New York, NY)
Assignee: Elysium Health, Inc.
A61K31/706A61K31/09A61P13/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,129,843
App. No.
16/607,531
Granted
Sep 28, 2021
Kind
B2
Abstract

Provided herein are methods and compositions related to treating and/or preventing kidney related diseases and disorders, treating and/or preventing acute kidney injury, and for improving kidney health in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.

Claims (45)

1. A method of treating or preventing kidney damage in a subject in need thereof comprising administering to the subject a composition comprising nicotinamide riboside and pterostilbene, wherein the administration of the composition comprises administering one or more doses of the composition, and each dose of the composition comprises at least 50 mg of pterostilbene.

2. The method of claim 1 , wherein the kidney damage is the result of decreased blood flood to the kidneys, back up of urine in the kidneys, sepsis, trauma, an autoimmune disease, cancer, drug-induced nephrotoxicity, or severe dehydration.

3. The method of claim 1 or 2 , wherein the kidney damage is caused by acute kidney injury.

4. A method of treating or preventing acute kidney injury comprising administering to a subject in need thereof a composition comprising nicotinamide riboside and pterostilbene, wherein the administration of the composition comprises administering one or more doses of the composition, and each dose of the composition comprises at least 50 mg of pterostilbene.

5. The method of claim 4 , wherein the acute kidney injury is a result of decreased blood flow to the kidneys.

6. The method of claim 5 , wherein the decreased blood flow is the result of hypotension, blood loss, severe diarrhea, heat attack, heart failure, decreased heart function, organ failure, drug-induced nephrotoxicity, trauma, or surgery.

7. The method of claim 6 , wherein the drug-induced nephrotoxicity is NSAID- induced nephrotoxicity.

8. The method of claim 4 , wherein the acute kidney injury is a result of cancer, sepsis, vasculitis, interstitial nephritis, scleroderma, tubular necrosis, glomerulonephritis, or thrombotic microangiopathy.

9. The method of claim 8 , wherein the cancer is multiple myeloma.

10. The method of claim 4 , wherein the acute kidney injury is the result of blockage of the urinary tract.

11. The method of claim 8 , wherein the blockage is caused by neurogenic bladder, retroperitoneal fibrosis, bladder cancer, prostate cancer, cervical cancer, an enlarged prostate, kidney stones, blood clots, or tumors.

12. A method of treating kidney disease in a subject in need thereof comprising administering to the subject a composition comprising nicotinamide riboside and pterostilbene, wherein the administration of the composition comprises administering one or more doses of the composition, and each dose of the composition comprises at least 50 mg of pterostilbene.

13. The method of claim 12 , wherein the kidney disease is the result of diabetes or hypertension.

14. The method of claim 12 , wherein the kidney disease is the result of a systemic disease, a viral disease, urinary tract infections, polycystic kidney disease, or a condition resulting in inflammation of glomeruli.

15. The method of claim 14 , wherein the systemic disease is lupus.

16. A method of increasing blood flow to the kidneys in a subject in need thereof comprising administering to the subject a composition comprising nicotinamide riboside and pterostilbene, wherein the administration of the composition comprises administering one or more doses of the composition, and each dose of the composition comprises at least 50 mg of pterostilbene.

17. The method of claim 16 , wherein the subject has acute kidney injury, kidney damage, or kidney disease.

18. The method of claim 16 , wherein each dose of the composition comprises at least 200 mg of nicotinamide riboside.

19. The method of claim 16 , wherein each dose of the composition comprises at least 250 mg of nicotinamide riboside.

20. The method of claim 16 , wherein each dose of the composition comprises at least 300 mg of nicotinamide riboside.

21. The method of claim 16 , wherein each dose of the composition comprises at least 350 mg of nicotinamide riboside.

22. The method of claim 16 , wherein each dose of the composition comprises at least 400 mg of nicotinamide riboside.

23. The method of claim 16 , wherein each dose of the composition comprises at least 450 mg of nicotinamide riboside.

24. The method of claim 16 , wherein each dose of the composition comprises at least 500 mg of nicotinamide riboside.

25. The method of claim 16 , wherein each dose of the composition comprises at least 550 mg of nicotinamide riboside.

26. The method of claim 16 , wherein each dose of the composition comprises at least 75 mg of pterostilbene.

27. The method of claim 16 , wherein each dose of the composition comprises at least 100 mg of pterostilbene.

28. The method of claim 16 , wherein each dose of the composition comprises at least 125 mg of pterostilbene.

29. The method of claim 16 , wherein each dose of the composition comprises at least 150 mg of pterostilbene.

30. The method of claim 16 , wherein two or more doses of the composition are administered.

31. The method of claim 16 , wherein thirty or more doses of the composition are administered.

32. The method of claim 16 , wherein fifty or more doses of the composition are administered.

33. The method of claim 16 , wherein one hundred or more doses of the composition are administered.

34. The method of claim 16 , wherein the dose of the composition is administered at least once a week.

35. The method of claim 16 , wherein the dose is administered at least twice a week.

36. The method of claim 16 , wherein the dose is administered at least three times a week.

37. The method of claim 16 , wherein the dose is administered at least once a day.

38. The method of claim 16 , wherein the dose is administered at least twice a day.

39. The method of claim 34 , wherein the doses are administered for at least 7 days.

40. The method of claim 34 , wherein the doses are administered for at least 30 days.

41. The method of claim 34 , wherein the doses are administered for at least 60 days.

42. The method of claim 34 , wherein the doses are administered for at least 90 days.

43. The method of claim 1 , wherein the composition is formulated as a pill, a tablet, or a capsule.

44. The method of claim 1 , wherein the composition is administered orally.

45. The method of claim 1 , wherein the composition is self-administered.

Assignments (2)
SECURITY INTEREST Recorded May 28, 2021
From: ELYSIUM HEALTH, INC.
To: VENTURE LENDING & LEASING IX, INC.
Reel/Frame 056388/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2019
From: MARCOTULLI, ERIC A.; ALMINANA, DANIEL A.; PERSHING GUARENTE, LEONARD; DELLINGER, RYAN; MORRIS, MARK
To: ELYSIUM HEALTH, INC.
Reel/Frame 050884/0116 →
Continuity (2)
Provisional Application 62489095 · Apr 24, 2017
Related Publication 20200069711A1 · Mar 5, 2020